Neumora Therapeutics Net Income

Neumora Therapeutics posts a net income of $-220M as of March 2026. That compares with $-260M in the prior-year period — up 13.8% year over year. That is below the sector sector average of $100M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Neumora Therapeutics's net income was $-260M. The latest reading is $-220M — a 13.8% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a net income near $100M is typical. Neumora Therapeutics's $-220M is lower that level. That is roughly 315.1% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of Neumora Therapeutics's financial statement story. At $-220M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for NMRA's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $100M), and (3) consistency with growth and profitability. This page covers the first two; Neumora Therapeutics's other metric pages and overview cover the third.